Table 4.
Results from adjusteda linear mixed models in weighted study population (N=444 subjects; N=1565 observations) representing percent change in plasma angiogenic biomarker concentration in association with an interquartile range increase in urinary phthalate metabolite concentration.
| sFlt-1 | PlGF | sFlt-1/PlGF ratio | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| percent change (95% CI) | p | percent change (95% CI) | p | percent change (95% CI) | p | |
| MEHP | −2.51 (−6.68, 1.84) | 0.254 | 3.79 (−1.92, 9.82) | 0.198 | −5.13 (−12.3, 2.59) | 0.187 |
| MEHHP | 1.87 (−2.45, 6.39) | 0.402 | −4.59 (−9.91, 1.04) | 0.109 | 8.37 (0.09, 17.3) | 0.048 |
| MEOHP | 1.20 (−2.95, 5.53) | 0.577 | −2.69 (−7.98, 2.90) | 0.339 | 5.67 (−2.20, 14.2) | 0.163 |
| MECPP | 1.98 (−2.68, 6.87) | 0.412 | −7.30 (−12.8, −1.51) | 0.014 | 10.9 (1.96, 20.6) | 0.016 |
| ΣDEHP | 1.74 (−2.85, 6.55) | 0.465 | −5.48 (−11.1, 0.45) | 0.070 | 8.99 (0.19, 18.6) | 0.045 |
| MBzP | 0.84 (−5.06, 7.10) | 0.786 | −0.22 (−7.27, 7.36) | 0.952 | 4.25 (−5.72, 15.3) | 0.418 |
| MBP | −0.94 (−6.16, 4.57) | 0.733 | −0.62 (−6.73, 5.89) | 0.847 | 2.12 (−6.41, 11.4) | 0.638 |
| MiBP | −3.35 (−9.46, 3.17) | 0.307 | −1.68 (−9.47, 6.79) | 0.688 | −1.20 (−11.8, 10.7) | 0.834 |
| MEP | −1.25 (−6.19, 3.95) | 0.630 | 3.25 (−3.27, 10.2) | 0.337 | −1.80 (−10.3, 7.46) | 0.693 |
| MCPP | −2.82 (−6.86, 1.40) | 0.188 | −2.27 (−7.56, 3.31) | 0.418 | 1.08 (−6.37, 9.12) | 0.784 |
| BPA | 6.43 (1.31, 11.8) | 0.013 | −4.98 (−11.1, 1.61) | 0.136 | 14.5 (4.33, 25.6) | 0.004 |
a
Models were adjusted for urinary specific gravity, gestational age at sample collection, maternal age, health insurance provider, and body mass index (time-varying), and included random intercepts and slopes for each study subject. Abbreviations: sFlt-1, soluble fms-like tyrosine kinase-1; PlGF, placental growth factor. Note: P-values were not corrected for multiple comparisons.